yingweiwo
  1. Home
  2. Products
  3. Signaling Pathways
  4. Anti-infection
  5. SARS-CoV

SARS-CoV

SARS-CoV

The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.

The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.

SARS-CoV related products

Structure Cat No. Product Name CAS No. Product Description
SARS-CoV-2 nsp3-IN-1 V76086 SARS-CoV-2 nsp3-IN-1 2892105-43-8 SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor (antagonist) with IC50 of 6.1 μM.
SARS-CoV-2 PLpro-IN-1 V105031 SARS-CoV-2 PLpro-IN-1 3053753-61-7 SARS-CoV-2 PLpro-IN-1 (Compound 85) is a non-covalent competitive inhibitor of SARS-CoV-2 PLpro with IC50 of 15.06 μM and Ki of 22.93 μM.
SARS-CoV-2-IN-10 V54397 SARS-CoV-2-IN-10 2722634-95-7 SARS-CoV-2-IN-10 is a potent and non-toxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with IC50 and EC50 of 0.13 and 1.03 nM respectively.
SARS-CoV-2-IN-100 V94382 SARS-CoV-2-IN-100 374543-46-1 SARS-CoV-2-IN-100 (Compound 172) is a SARS-CoV-2 inhibitor that exhibits broad-spectrum antiviral activity against different SARS-CoV-2 variants.
SARS-CoV-2-IN-101 V93757 SARS-CoV-2-IN-101 SARS-CoV-2-IN-101 (Compound 10O) is a potent, oral SARS-CoV-2 inhibitor with an EC50 value of 0.64 µM against HCoV-229E.
SARS-CoV-2-IN-102 V93274 SARS-CoV-2-IN-102 3055041-73-8 SARS-CoV-2-IN-102 (Example 58) is a SARS-CoV papain-like protease (SARS-CoV PLpro) inhibitor with IC50 <100 nM.
SARS-CoV-2-IN-106 V103983 SARS-CoV-2-IN-106 2863607-73-0 SARS-CoV-2-IN-106 (Compound 19) is a SARS-CoV-2 papain inhibitor with IC50 values of 0.44 μM and 0.18 μM for papain and viral replication, respectively.
SARS-CoV-2-IN-107 V104908 SARS-CoV-2-IN-107 SARS-CoV-2-IN-107 (Compound A7) is an inhibitor of SARS-CoV-2 3CLpro with IC50 of 261.3 nM.
SARS-CoV-2-IN-108 V104665 SARS-CoV-2-IN-108 SARS-CoV-2-IN-108 (Compound 29) is an inhibitor of SARSCoV-2 papain-like protease with IC50 of 0.14 µM.
SARS-CoV-2-IN-11 V54409 SARS-CoV-2-IN-11 2722635-28-9 SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with IC50 and EC50 of 0.17 and 1.45 nM, respectively.
SARS-CoV-2-IN-25 disodium V77713 SARS-CoV-2-IN-25 disodium SARS-CoV-2-IN-25 (Compound CP026) disodium is a potent inhibitor of SARS-CoV-2 spike pseudoparticle transduction with IC50 of 1.6 μM.
SARS-CoV-2-IN-31 V37548 SARS-CoV-2-IN-31 1017691-52-9 SARS-CoV-2-IN-31 is a potent COVID-19 inhibitor.
SARS-CoV-2-IN-32 V37544 SARS-CoV-2-IN-32 96068-42-7 SARS-CoV-2-IN-32 (compound 3g) is a COVID-19 inhibitor.
SARS-CoV-2-IN-33 V37543 SARS-CoV-2-IN-33 299919-79-2 SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor.
SARS-CoV-2-IN-34 V81366 SARS-CoV-2-IN-34 SARS-CoV-2-IN-34 (S-20-1) is a pan-coronavirus (CoV) fusion inhibitor (antagonist) with broad-spectrum inhibitory activity that can penetrate the BBB (blood-brain barrier).
SARS-CoV-2-IN-35 V54404 SARS-CoV-2-IN-35 2757763-47-4 SARS-CoV-2-IN-35 is an orally bioactive SARS-CoV-2 M pro inhibitor (antagonist) with a Ki of 12.1 nM.
SARS-CoV-2-IN-36 V80058 SARS-CoV-2-IN-36 SARS-CoV-2-IN-36 is a potent inhibitor of SARS-CoV-2 Mpro (SARS-CoV) with IC50 of 2.37 μM and a Kd of 1.19 μM in an enzymatic assay.
SARS-CoV-2-IN-38 V54429 SARS-CoV-2-IN-38 2882823-27-8 SARS-CoV-2-IN-38 (compound 24) is a SARS-CoV-2 inhibitor (antagonist) with good oral bioavailability (F) in mice (F%=39.75%).
SARS-CoV-2-IN-39 V54396 SARS-CoV-2-IN-39 2882823-03-0 SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor (antagonist) with EC50 of 1 μM.
SARS-CoV-2-IN-40 V78846 SARS-CoV-2-IN-40 SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor.
Contact Us
Tel: 1-708-310-1919 Fax: 1-708-557-7486 Email: sales@invivochem.com Frequently Asked Questions
Subscribe to our E-newsletter
Name
E-mail

Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved

linkedin facebook
Contact Us
Home Product Cart Member